Four-Company Consortium Launches AI-Driven Drug Discovery for Subarachnoid Hemorrhage Complications
核心洞察
Proteros biostructures, Qanatpharma (搜索), Zuse Institute Berlin (搜索), and Enamine (搜索) have formed a research collaboration to develop novel therapeutics for delayed cerebral ischemia (搜索), a life-threatening complication of subarachnoid hemorrhage (搜索).
The partnership leverages generative AI technology from ZIB to accelerate early-stage drug discovery targeting cerebrovascular resistance mechanisms compromised in SAH patients.
Compound screening efforts are already underway, with in-vitro validation studies planned for the second half of 2025, representing the most significant effort to address microvascular dysfunction-driven diseases.
An international consortium of four companies has launched a groundbreaking research collaboration to develop first-in-class therapeutics for delayed cerebral ischemia (搜索) (DCI), a life-threatening complication of subarachnoid hemorrhage (搜索) (SAH). The partnership, announced on July 9, 2025, brings together Proteros biostructures GmbH (搜索) of Germany, Qanatpharma (搜索) of Switzerland, Zuse Institute Berlin (搜索) (ZIB), and Ukraine-based Enamine (搜索) to leverage generative artificial intelligence in accelerating drug discovery for cerebrovascular conditions.
Targeting Critical Unmet Medical Need
Subarachnoid hemorrhage (搜索) represents a severe form of stroke (搜索) caused by bleeding into the space surrounding the brain. A leading complication for SAH survivors is delayed cerebral ischemia (搜索), which reduces cerebral perfusion and may result in long-term neurological damage, disability, or death. Current treatment options remain largely ineffective, with nimodipine, a calcium channel blocker approved as standard of care for SAH, failing to target the molecular mechanism underlying DCI.
"Delayed cerebral ischemia (搜索) is a major contributor to poor outcomes following subarachnoid hemorrhage (搜索), and current treatment options remain limited," said Dr. Steffen-Sebastian Bolz, Chief Medical and Scientific Officer at Qanatpharma (搜索). "By building this consortium, we are bringing together the brightest machine learning engineers, chemists, structural biologists, and other scientists to tackle this critical complication. Together, we aim to accelerate the development of a targeted therapy that could significantly improve recovery and long-term outcomes for patients affected by SAH."
AI-Powered Drug Discovery Platform
The collaboration focuses on a protein target identified by Qanatpharma (搜索) that helps regulate cerebrovascular resistance in the brain—a mechanism shown to be compromised in patients with SAH. The partnership spans the entire drug discovery process, from early generative molecular design and docking studies conducted by ZIB using proprietary algorithms, through REAL®-directed compound synthesis by Enamine (搜索), to validation of hit compounds by Proteros using their structure-based drug discovery platform.
ZIB contributes deep expertise in high-performance computing, ligand docking, and AI-based generative ligand design. Enamine (搜索) provides access to ultra-large chemical space via the REAL® approach, with unparalleled compound libraries including 4.5 million screening compounds and 350,000 building blocks in stock, along with synthesis capabilities for rapid translation of virtual hits into novel chemical matter. Proteros leverages its drug discovery platform to deliver structurally enabled qualified hits and lead series with fully characterized mode-of-action.
Research Progress and Timeline
The multiparty collaboration has already initiated compound screening efforts and plans to proceed to in-vitro validation studies in the second half of 2025. According to the partners, this represents the most significant effort to date toward understanding and ultimately treating diseases driven by microvascular dysfunction with innovative compounds.
"Our consortium with strong complementary expertise leverages the challenging opportunity to navigate towards the most suitable first-in class drug candidate by pushing the limits of accessible chemical space," said DSc. Yurii Moroz, Vice President of Sales and Marketing at Enamine (搜索).
Dr. Torsten Neuefeind, founder and CEO of Proteros, expressed enthusiasm about the collaboration's potential: "We are pleased about this collaboration aiming to address a drug target identified by QP which could transform the treatment of life-threatening complications."
Industry Trend Toward AI Integration
The partnership reflects a broader industry trend of integrating generative AI tools into pharmaceutical research and development. Other collaborations announced in 2025 include agreements between Delaware-based Incyte and California-based Genesis Therapeutics for AI-driven small-molecule medicine development, and St. Louis-based Emerson's AI-enhanced manufacturing operations approach.
According to industry experts, generative AI represents a top trend for pharmaceutical companies' operational approaches. The SAH collaboration sets a precedent for using generative AI technologies to accelerate early-stage drug discovery for cerebrovascular conditions, combining detailed insights into microvascular complications with computational innovation, medicinal chemistry, protein sciences, biophysics, biochemistry, and structural biology including cryo-EM techniques.